By mapping a patient’s genome, and their tumor’s, with whole-genome sequencing, physicians can use more targeted therapies.
Tigatuzumab, developed at UAB with Daiichi-Sankyo, targets aggressive, hard-to-treat tumors that make up 25 percent of all breast cancers
UAB Comprehensive Cancer Center helps drop cancer disparities while brain tumor research holds promise for new therapies to fight gliomas
NASA-developed technology designed to grow plants in space proves effective at treating cancer patients’ mouth sores in a UAB clinical trial.
There are 12 million cancer survivors in the U.S., but poor nutrition is increasing deaths from heart disease and other chronic illnesses.
A researcher in the UAB Comprehensive Cancer Center has been selected for the inaugural Ovarian Cancer Academy Award, part of the U.S. Department of Defense funding for cancer research. Assistant Professor Charles Landen, M.D., of the Division of Gynecologic Oncology, is one of seven early career investigators chosen for the grant. The award is $1.06 million from the Office of Congressionally Directed Medical Research.Landen works to identify and characterize a subpopulation of ovarian cancer cells that have enhanced ability to survive chemotherapy and cause recurrence. Understanding this class of cells may lead to discoveries of key pathways than can be targeted with novel anti-cancer therapies.